Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients
Article first published online: 14 NOV 2006
Journal of the European Academy of Dermatology and Venereology
Volume 21, Issue 1, pages 72–78, January 2007
How to Cite
Madej, A., Reich, A., Orda, A. and Szepietowski, J. (2007), Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 21: 72–78. doi: 10.1111/j.1468-3083.2006.01869.x
- Issue published online: 14 NOV 2006
- Article first published online: 14 NOV 2006
- Received: 23 September 2005, accepted 27 January 2006; DOI: 10.1111/j.1468-3083.2006.01869.x
- adhesion molecules;
- vascular adhesion protein-1
Background Vascular adhesion protein (VAP)-1 is an adhesion molecule with an enzymatic activity that partakes in the migration process of lymphocytes.
Objectives The aim of this study was to investigate the expression of VAP-1 in the skin and serum of psoriatic patients.
Material and methods Seventy-one patients suffering from psoriasis aged between 23 and 89 years were included in the study. The mean psoriasis severity assessed according to the psoriasis area and severity index was 14.2 ± 9.6 points. The soluble VAP-1 serum concentration was evaluated by ELISA and VAP-1 expression in the skin (nine patients) immunohistochemically.
Results The serum concentration of soluble VAP-1 was significantly higher in psoriatic patients than in healthy controls (403.4 ± 130.8 ng/mL vs. 246.4 ± 68.0 ng/mL; P < 0.0001). No significant relationships were found between sVAP-1 concentration and studied clinical parameters, except the presence of pruritus. Mean number of VAP-1 positive vessels in psoriatic skin, both lesional (19.8 ± 1.4) and non-lesional (9.4 ± 1.4), was significantly higher than in healthy skin (5.4 ± 1.5; P < 0.005). Lesional psoriatic skin demonstrated significantly more VAP-1 positive vessels than non-lesional skin (P < 0.01).
Conclusions Significant overexpression of VAP-1 in both lesional and non-lesional psoriatic skin and higher serum level of soluble VAP-1 in psoriatic patients may indicate the role of VAP-1 in chronic inflammation occurring in psoriasis. However, because of lack of correlation between soluble VAP-1 serum levels and psoriasis severity this hypothesis needs further investigation.